^
Association details:
| Biomarker: | ANGPT2 elevation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study
Published date:
07/04/2021
Excerpt:
Patients with Ang-2 early increased levels (n=42) had a trend for a better outcome (HR for PFS: 0.72 [95%CI:0.48-1.08], P=0.095; HR for OS: 0.77 [95%CI:0.51-1.16], P=0.204) than those with Ang-2 early decreased levels (n=58)....the association of d1 Ang-2 levels with PFS was confirmed...Ang-2 baseline levels as prognostic marker and its early modulation as a predictor of benefit from regorafenib in mCRC patients.
DOI:
https://doi.org/10.1016/j.annonc.2021.05.044
Trial ID:
